Literature DB >> 12601108

CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study.

D Strozyk1, K Blennow, L R White, L J Launer.   

Abstract

OBJECTIVE: To investigate the relationship of amyloid neuropathology to postmortem CSF Abeta 42 levels in an autopsy sample of Japanese American men from the population-based Honolulu-Asia Aging Study.
METHODS: In 1991, participants were assessed and diagnosed with dementia (including subtype) based on published criteria. At death CSF was obtained from the ventricles. Neuritic plaques (NP) and diffuse plaques in areas of the neocortex and hippocampus were examined using Bielschowsky silver stains. Cerebral amyloid angiopathy (CAA) was measured by immunostaining for beta4 amyloid in cerebral vessels in the neocortex. Neuropathologically confirmed AD was diagnosed using Consortium to Establish a Registry for Alzheimer's Disease criteria. In 155 autopsy samples, log transformed linear regression models were used to examine the association of NP and CAA to Abeta 42 levels, controlling for clinical dementia severity, time between diagnosis and death, age at death, brain weight, hours between death and collection of CSF, education, and APOE genotype.
RESULTS: Higher numbers of NP in the neocortex (p trend = 0.001) and in the hippocampus (p trend = 0.03) were strongly associated with lower levels of Abeta 42. Individuals with CAA had lower Abeta 42 levels (beta coefficient = -0.48; 95% CI -0.9, -0.1). Compared to participants with a diagnosis of clinical dementia, those with pathologically confirmed AD had lower Abeta 42 levels (beta coefficient = -0.74; 95% CI -1.4, -0.1).
CONCLUSION: The current study suggests that lower Abeta 42 levels reflect neuropathologic processes implicated in amyloid-related pathologies, such as NP and CAA.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12601108     DOI: 10.1212/01.wnl.0000046581.81650.d0

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  212 in total

Review 1.  Quantitative structural MRI for early detection of Alzheimer's disease.

Authors:  Linda K McEvoy; James B Brewer
Journal:  Expert Rev Neurother       Date:  2010-11       Impact factor: 4.618

2.  Conformational differences between two amyloid β oligomers of similar size and dissimilar toxicity.

Authors:  Ali Reza A Ladiwala; Jeffrey Litt; Ravi S Kane; Darryl S Aucoin; Steven O Smith; Swarnim Ranjan; Judianne Davis; William E Van Nostrand; Peter M Tessier
Journal:  J Biol Chem       Date:  2012-04-30       Impact factor: 5.157

Review 3.  Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives.

Authors:  Harald Hampel; Richard Frank; Karl Broich; Stefan J Teipel; Russell G Katz; John Hardy; Karl Herholz; Arun L W Bokde; Frank Jessen; Yvonne C Hoessler; Wendy R Sanhai; Henrik Zetterberg; Janet Woodcock; Kaj Blennow
Journal:  Nat Rev Drug Discov       Date:  2010-07       Impact factor: 84.694

4.  Metabolomic changes in autopsy-confirmed Alzheimer's disease.

Authors:  Rima Kaddurah-Daouk; Steve Rozen; Wayne Matson; Xianlin Han; Christine M Hulette; James R Burke; P Murali Doraiswamy; Kathleen A Welsh-Bohmer
Journal:  Alzheimers Dement       Date:  2010-11-13       Impact factor: 21.566

5.  Beta amyloid, tau, neuroimaging, and cognition: sequence modeling of biomarkers for Alzheimer's Disease.

Authors:  S Duke Han; Jonathan Gruhl; Laurel Beckett; Hiroko H Dodge; Nikki H Stricker; Sarah Farias; Dan Mungas
Journal:  Brain Imaging Behav       Date:  2012-12       Impact factor: 3.978

6.  The impact of cerebrospinal fluid biomarkers on the diagnosis of Alzheimer's disease.

Authors:  Sebastiaan Engelborghs; Nathalie Le Bastard
Journal:  Mol Diagn Ther       Date:  2012-06-01       Impact factor: 4.074

7.  Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.

Authors:  Jon B Toledo; Henrik Zetterberg; Argonde C van Harten; Lidia Glodzik; Pablo Martinez-Lage; Luisella Bocchio-Chiavetto; Lorena Rami; Oskar Hansson; Reisa Sperling; Sebastiaan Engelborghs; Ricardo S Osorio; Hugo Vanderstichele; Manu Vandijck; Harald Hampel; Stefan Teipl; Abhay Moghekar; Marilyn Albert; William T Hu; Jose A Monge Argilés; Ana Gorostidi; Charlotte E Teunissen; Peter P De Deyn; Bradley T Hyman; Jose L Molinuevo; Giovanni B Frisoni; Gurutz Linazasoro; Mony J de Leon; Wiesje M van der Flier; Philip Scheltens; Kaj Blennow; Leslie M Shaw; John Q Trojanowski
Journal:  Brain       Date:  2015-07-27       Impact factor: 13.501

Review 8.  Do CSF Biomarkers Predict Progression to Cognitive Impairment in Parkinson's disease patients? A Systematic Review.

Authors:  Katherine Leaver; Kathleen L Poston
Journal:  Neuropsychol Rev       Date:  2015-12-01       Impact factor: 7.444

9.  Amyloid-β associated volume loss occurs only in the presence of phospho-tau.

Authors:  Rahul S Desikan; Linda K McEvoy; Wesley K Thompson; Dominic Holland; J Cooper Roddey; Kaj Blennow; Paul S Aisen; James B Brewer; Bradley T Hyman; Anders M Dale
Journal:  Ann Neurol       Date:  2011-10-14       Impact factor: 10.422

Review 10.  Emerging biomarkers in cognition.

Authors:  Meredith Wicklund; Ronald C Petersen
Journal:  Clin Geriatr Med       Date:  2013-11       Impact factor: 3.076

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.